Associated Papers
Novel molecular mechanisms of FLT3 deregulation: from the acute myeloid leukemia experience to therapeutic insights in acute lymphoblastic leukemia.
Lo Schiavo F et al.
Molecular Cancer, 2025
In silico and in vitro study of FLT3 inhibitors and their application in acute myeloid leukemia.
Carranza-Aranda AS et al.
Molecular Medicine Reports, 2024
Landscape of FLT3 Variations Associated with Structural and Functional Impact on Acute Myeloid Leukemia: A Computational Study.
Mirza Z et al.
International Journal of Molecular Sciences, 2024
Indole-based FLT3 inhibitors and related scaffolds as potential therapeutic agents for acute myeloid leukemia.
Ezelarab HAA et al.
Bmc Chemistry, 2023
The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms.
Ferng TT et al.
Molecular Cancer Therapeutics, 2022
Exploring the Resistance Mechanisms of Distal D835V Mutation in FLT3 to Inhibitors.
Wang Z et al.
Oxidative Medicine and Cellular Longevity, 2022
Selectively targeting FLT3-ITD mutants over FLT3-wt by a novel inhibitor for acute myeloid leukemia.
Wang A et al.
Haematologica, 2021
Rare and novel RUNX1 fusions in myeloid neoplasms: A single-institute experience.
Aypar U et al.
Genes, Chromosomes & Cancer, 2021
Deciphering the molecular mechanism of FLT3 resistance mutations.
Georgoulia PS et al.
The Febs Journal, 2020
FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development.
Kiyoi H et al.
Cancer Science, 2020
First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations.
Daver N et al.
Frontiers in Oncology, 2020
FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies.
Kennedy VE et al.
Frontiers in Oncology, 2020
Insights Into the Resistance Mechanisms of Inhibitors to FLT3 F691L Mutation via an Integrated Computational Approach.
Sun Y et al.
Frontiers in Pharmacology, 2019
Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance.
Staudt D et al.
International Journal of Molecular Sciences, 2018
Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies.
Zhou J et al.
World Journal of Clinical Oncology, 2018
Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy.
Gill H et al.
International Journal of Molecular Sciences, 2016
FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.
Ma HS et al.
Cancer Research, 2014
Targeting oncoprotein stability overcomes drug resistance caused by FLT3 kinase domain mutations.
Yu C et al.
Plos One, 2014
The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220.
Pauwels D et al.
Haematologica, 2012
Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.
Zirm E et al.
British Journal of Haematology, 2012
A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl.
Choi HG et al.
Journal of Medicinal Chemistry, 2010
Investigational drugs targeting FLT3 for leukemia.
Ustun C et al.
Expert Opinion on Investigational Drugs, 2009
Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin.
Barry EV et al.
Blood, 2007
Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Kancha RK et al.
Experimental Hematology, 2007
The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.
Lierman E et al.
Haematologica, 2007
Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia.
Cools J et al.
Cancer Research, 2004